CN103948900B - A kind of preparation method for the treatment of atrophic gastritis Tibetan medicine - Google Patents
A kind of preparation method for the treatment of atrophic gastritis Tibetan medicine Download PDFInfo
- Publication number
- CN103948900B CN103948900B CN201410206297.7A CN201410206297A CN103948900B CN 103948900 B CN103948900 B CN 103948900B CN 201410206297 A CN201410206297 A CN 201410206297A CN 103948900 B CN103948900 B CN 103948900B
- Authority
- CN
- China
- Prior art keywords
- tibetan medicine
- fructus piperis
- group
- preparation
- tibetan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of preparation method for the treatment of atrophic gastritis Tibetan medicine, be adopted co-grinding method or decoction and alcohol sedimentation technique or ethanol extract from water precipitation to make active component be according to a certain weight ratio prepared from by Semen Granati, Cortex Cinnamomi, Fructus Amomi Rotundus, Fructus Piperis Longi, Flos Carthami, Rhizoma Zingiberis, Fructus Piperis, Sal Ammoniacus, Capsicum frutescens Linn., Tibetan Caulis Akebiae, Flos Bombacis Malabarici, the conventional dosage form for oral administration of any one can be prepared into.This Tibetan medicine has cold relieving eliminating mass and relieving fullness, helps digestion, and adjusts the function of liver stomach reinforcing.For accumulation of food in the stomach and intes tine due to indigestion, gastrointestinal and hepatalgia, except cold liver withers disease, atrophic gastritis etc.
Description
Technical field
The present invention relates to a kind of preparation method for the treatment of atrophic gastritis Tibetan medicine, belong to Tibetan medicine field.
Background technology
Atrophic gastritis also claims chronic atrophic gastritis, and with gastric epithelial and body of gland atrophy, decreased number, gastric mucosa is thinning, and mucosa basic unit thickens, or companion's gland metaplasia and intestinal gland metaplasia, or has atypical hyperplasia to be the chronic digestive system disease of feature.Often show as epigastrium dull pain, distension, belch, inappetence, or become thin, anemia etc., without specificity.A kind of many paathogenic factors disease and precancerous lesion.
Along with the raising of people's living standard, the sickness rate of the growth chronic gastritis at age is more and more higher, can make patient's canceration of 2%, and treat thorny, there is no specific medicament radical cure at present.
Modern medicine makes the cure rate of atrophic gastritis be significantly improved, but relapse rate is up to more than 80%, because primary disease belongs to chronic disease, is difficult to radical cure, easily recurs, serious harm human health.
Therefore, there is tight demand to the Tibetan medicinal preparation that curative effect better treats atrophic gastritis in people.Up to now, any report about Tibetan medicinal composition of the present invention and preparation method thereof is not also found.The present inventor through repeatedly studying, and by the checking repeatedly of animal and clinical trial, finally have found Tibetan medicine oral drugs and the preparation method of the treatment atrophic gastritis of better curative effect, thus completes the present invention.
Summary of the invention
The object of the invention is just to provide a kind of preparation method of more effectively treating atrophic gastritis Tibetan medicine.
The present invention is a kind of Tibetan medicine, be be made up of active component or be made up of active component and pharmaceutically acceptable adjuvant, wherein said active component is made up of following bulk drugs: Semen Granati, Cortex Cinnamomi, Fructus Amomi Rotundus, Fructus Piperis Longi, Flos Carthami, Rhizoma Zingiberis, Fructus Piperis, Sal Ammoniacus, Capsicum frutescens Linn., Tibetan Caulis Akebiae, Flos Bombacis Malabarici.
It has selected Semen Granati, Cortex Cinnamomi, Fructus Amomi Rotundus, Fructus Piperis Longi, Flos Carthami, Rhizoma Zingiberis, Fructus Piperis, Sal Ammoniacus, Capsicum frutescens Linn., Tibetan Caulis Akebiae, Flos Bombacis Malabarici carry out combining as crude drug, and wherein (1) Semen Granati is the dry seed of Punicaceae plant pomegranate PunicagranatumL..Cure mainly Baconic's sympotoms caused by cold factors, cold syndrome of the stomach disease and all gastropathy.There are aid digestion, anti-gastric-ulcer, astringing intestine to stop diarrhea hemostasis, vessel softening, blood fat reducing and blood glucose, reduce the several functions such as cholesterol.(2) Cortex Cinnamomi is the dry bark of canella Cortex Cinnamomi CinnamomumcassiaPresl.There is benefit fire supporing yang, let the fire back to its origin, dispersing cold for relieving pain, promoting blood circulation to restore menstrual flow.For sexual impotence, cold womb, chills and pain of the waist and kness, suffers from a deficiency of the kidney and breathes heavily, dizziness due to yang deficiency, conjunctival congestion pharyngalgia, trusted subordinate's cold type of pain, and deficiency and coldness is vomited and diarrhoea, colic of cold type, renal mass, amenorrhea, dysmenorrhea.(3) Fructus Amomi Rotundus is the dry mature fruit of zingiberaceous plant Fructus Amomi Rotundus AmomumkravanhPierreexGagnep. or amomum compactum Soland ex Maton AmomumcompactumSolandexMaton.There is removing dampness to disappear painful abdominal mass, circulation of qi promoting warming middle-JIAO, effect of appetite-stimulating indigestion-relieving.For turbid damp obstructing in middle-JIAO, anorexia, hygropyrexia from the beginning of, uncomfortable in chest not hungry, cold-damp vomiting, chest and abdomen swelling and pain, food stagnation does not disappear.(4) Fructus Piperis Longi is the nearly ripe or mature fruit cluster of drying of Piperaceae plant Fructus Piperis Longi PiperlongumL..There is warming spleen and stomach for dispelling cold, the function of therapeutic method to keep the adverse QI flowing downwards pain relieving.For coldness and pain in the epigastrium, vomiting, has loose bowels, QI stagnated by cold, obstruction of qi in the chest and cardialgia, headache, toothache.(5) Flos Carthami is the dried floral of feverfew Flos Carthami CarthamustinctoriusL..There is promoting blood circulation to restore menstrual flow, effect of eliminating stasis to stop pain.For amenorrhea, dysmenorrhea, lochia ， mass in the abdomen mass in the abdomen, injury from falling down, skin infection swells and ache.(6) Rhizoma Zingiberis is the dry rhizome of zingiber ZingiberofficinaleRosc..Have warming spleen and stomach for dispelling cold, recuperating depleted YANG is promoted blood circulation, effect of dampness expectorant.For coldness and pain in the epigastrium, vomiting is had loose bowels, and cold extremities faint pulse, phlegm retention is breathed with cough.(7) Fructus Piperis is the nearly ripe or mature fruit of drying of Piperaceae plant Fructus Piperis PipernigrumL..There is warming spleen and stomach for dispelling cold, the therapeutic method to keep the adverse QI flowing downwards, effect of expectorant.For gastrofrigid vomiting, stomachache is had loose bowels, inappetence, epilepsy abundant expectoration.(8) Sal Ammoniacus is halogenide class halite race halite.There is stomach warming relieving constipation, effect of relieving distension.For the complication of " Baconic " and " dragon ", abdominal distention borborygmus, constipation, choke,hiccup and regurgitation.(9) Capsicum frutescens Linn. is the dry mature fruit of plant of Solanaceae Capsicum frutescens Linn. CapsicumfrutescensL..Have and promote stomach temperature, effect of parasite killing.For cold syndrome of the stomach, hemorrhoid, parasitosis.(10) hide Caulis Akebiae be the congener spent in vain of cohosh Clematis montana ClematismontanaBuch.-Ham. and opening several band leaf and the biennial branch of flowers and fruits.There is stomach warming, cold expelling, spleen invigorating, the effect helped digestion.For the cold mass in the abdomen of stomach, cold diarrhoea and edema chronic gastritis.(11) Flos Bombacis Malabarici is the dried floral of Bombacaceae plant Flos Bombacis Malabarici Gossampinusmalobarica (DC.) Merr..There is clearing away lung-heat, liver-heat, heat in the heart, digestant effect.For the heart, lung, gallbladder, liver-heat and dyspepsia.
Tibetan medicine of the present invention is the diseases such as the dyspepsia that causes for the treatment of cold syndrome of the stomach, and in side, Semen Granati is the king of stomach medicine, the monarch in side, the merit of tool cold expelling stomach warming; Cortex Cinnamomi, Fructus Amomi Rotundus, Fructus Piperis Longi, Tibetan Caulis Akebiae etc. are the medicine of invigorating the spleen and regulating the stomach, warming spleen and stomach for dispelling cold, help the power of Semen Granati warming stomach for dispelling cold; Flos Carthami promoting blood circulation and hemostasis; Sal Ammoniacus promotes stomach-fire, dissolving lump and resolving mass; The Sheng of the mediation such as Rhizoma Zingiberis, Fructus Piperis, Capsicum frutescens Linn. dragon, Baconic is real; Flos Bombacis Malabarici clearing away lung-heat, liver-heat, heat in the heart are aid digestion; All medicines share, and play stomach warming altogether and to help digestion, protect the liver the effect of stomach invigorating.Made by these drug regimens each efficacy of drugs produce synergism, thus effectively can treat atrophic gastritis.
The consumption of Tibetan medicine active component of the present invention is also through inventor and gropes in a large number to sum up and draw, each crude drug consumption for all to have good therapeutic effect within the scope of following concrete weight proportion:
Semen Granati 37.5 ~ 112.5g, Cortex Cinnamomi 25 ~ 75g, Fructus Amomi Rotundus 25 ~ 75g, Fructus Piperis Longi 25 ~ 75g, Flos Carthami 5 ~ 15g, Rhizoma Zingiberis 5 ~ 15g, Fructus Piperis 5 ~ 15g, Sal Ammoniacus 5 ~ 15g, Capsicum frutescens Linn. 5 ~ 15g, Tibetan Caulis Akebiae 12.5 ~ 37.5g, Flos Bombacis Malabarici 12.5 ~ 37.5g.
Be preferably: Semen Granati 60 ~ 90g, Cortex Cinnamomi 40 ~ 60g, Fructus Amomi Rotundus 40 ~ 60g, Fructus Piperis Longi 40 ~ 60g, Flos Carthami 8 ~ 12g, Rhizoma Zingiberis 8 ~ 12g, Fructus Piperis 8 ~ 12g, Sal Ammoniacus 8 ~ 12g, Capsicum frutescens Linn. 8 ~ 12g, Tibetan Caulis Akebiae 20 ~ 30g, Flos Bombacis Malabarici 20 ~ 30g.
More preferably: Semen Granati 75g, Cortex Cinnamomi 50g, Fructus Amomi Rotundus 50g, Fructus Piperis Longi 50g, Flos Carthami 10g, Rhizoma Zingiberis 10g, Fructus Piperis 10g, Sal Ammoniacus 10g, Capsicum frutescens Linn. 10g, Tibetan Caulis Akebiae 25g, Flos Bombacis Malabarici 25g.
The preparation of Tibetan medicine active component of the present invention can be made by direct for the crude drug of above-mentioned consumption co-grinding; Also the crude drug of above-mentioned consumption can be adopted the conventional method of Chinese medicine preparation such as decoction and alcohol sedimentation technique or ethanol extract from water precipitation (see " pharmaceutics of Chinese drugs " 73rd ~ 74 pages of Cao Chunlin chief editor, Science and Technology of Shanghai publishing house publishes in November, 1986) to obtain.
The active component of Tibetan medicine of the present invention can add various customary adjuvant required when preparing different dosage form, as disintegrating agent, lubricant, binding agent etc. with the method for Chinese medicinal of routine (see Cao Chunlin chief editor " pharmaceutics of Chinese drugs ", Science and Technology of Shanghai publishing house in November, 1986 publishes) be prepared into any one and commonly use peroral dosage form, as powder, pill, capsule, granule, tablet etc.
Tibetan medicine of the present invention has cold relieving eliminating mass and relieving fullness, helps digestion, and adjusts effect of liver stomach reinforcing.For accumulation of food in the stomach and intes tine due to indigestion, gastrointestinal and hepatalgia, except cold liver withers disease, atrophic gastritis etc.
The usage and dosage of Tibetan medicine of the present invention is: oral; A 1 ~ 1.5g, 1 ~ 3 time on the one.
[detailed description of the invention]
Carry out the preparation method setting forth Tibetan medicine of the present invention further by the following examples.
The preparation of [embodiment 1] Tibetan medicine powder of the present invention:
Take Semen Granati 75g, Cortex Cinnamomi 50g, Fructus Amomi Rotundus 50g, Fructus Piperis Longi 50g, Flos Carthami 10g, Rhizoma Zingiberis 10g, Fructus Piperis 10g, Sal Ammoniacus 10g, Capsicum frutescens Linn. 10g, hide Caulis Akebiae 25g, Flos Bombacis Malabarici 25g, be jointly ground into fine powder after mixing, mixing, subpackage, obtains powder.
The preparation of [embodiment 2] Tibetan medicine pill of the present invention:
Take Semen Granati 37.5g, Cortex Cinnamomi 25g, Fructus Amomi Rotundus 25g, Fructus Piperis Longi 25g, Flos Carthami 5g, Rhizoma Zingiberis 5g, Fructus Piperis 5g, Sal Ammoniacus 5g, Capsicum frutescens Linn. 5g, hide Caulis Akebiae 12.5g, Flos Bombacis Malabarici 12.5g, jointly fine powder is ground into after mixing, mixing, with water pill, dry below 60 DEG C, polishing, packaging, obtains pill.
The preparation of [embodiment 3] Tibetan medicine granule of the present invention:
Take Semen Granati 112.5g, Cortex Cinnamomi 75g, Fructus Amomi Rotundus 75g, Fructus Piperis Longi 75g, Flos Carthami 15g, Rhizoma Zingiberis 15g, Fructus Piperis 15g, Sal Ammoniacus 15g, Capsicum frutescens Linn. 15g, hide Caulis Akebiae 37.5g, Flos Bombacis Malabarici 37.5g, jointly fine powder is ground into after mixing, mixing, add adjuvant and make granule, dry below 60 DEG C, granulate, subpackage, obtains granule.
The preparation of [embodiment 4] Tibetan medicine capsule of the present invention:
Take Semen Granati 60g, Cortex Cinnamomi 40g, Fructus Amomi Rotundus 40g, Fructus Piperis Longi 40g, Flos Carthami 8g, Rhizoma Zingiberis 8g, Fructus Piperis 8g, Sal Ammoniacus 8g, Capsicum frutescens Linn. 8g, hide Caulis Akebiae 20g, Flos Bombacis Malabarici 20g, jointly be ground into fine powder after mixing, mixing, load gelatine capsule, subpackage, obtains capsule.
The preparation of [embodiment 5] Tibetan medicine tablet of the present invention:
Take Semen Granati 90g, Cortex Cinnamomi 60g, Fructus Amomi Rotundus 60g, Fructus Piperis Longi 60g, Flos Carthami 12g, Rhizoma Zingiberis 12g, Fructus Piperis 12g, Sal Ammoniacus 12g, Capsicum frutescens Linn. 12g, hide Caulis Akebiae 30g, Flos Bombacis Malabarici 30g, jointly fine powder is ground into after mixing, mixing, add adjuvant and make granule, dry below 60 DEG C, granulate, tabletting, subpackage, obtains tablet.
Set forth the beneficial effect of Tibetan medicine of the present invention further below by way of test example, these test examples include pharmacodynamics test and the clinical observation on the therapeutic effect test of Tibetan medicine embodiment 1 powder of the present invention.
[test example 1] Tibetan medicine embodiment 1 powder of the present invention is to the effect of analgesia, antiinflammatory action and kinds of experiments gastric ulcer model:
Test material: anthology invention Tibetan medicine embodiment 1 powder; XIANGSHA YANGWEI WAN, lot number: 20100305, as if the western Pharmacy stock Co., Ltd in effluent south produces; Aspirin Vc enteric coatel tablets are produced by Harbin Pharmaceutical Group Sanjing Qianhe Wangkui Pharmaceutical Co., Ltd., lot number 20100312; Indometacin enteric-coated tablet is produced by Shanxi Yun He pharmaceutical Co. Ltd, lot number 20091006; Dimethylbenzene is produced by the huge chemical reagent factory in Dongli District, Tianjin, lot number 2010408; AZO-blue is produced by bio tech ltd of China one, Shanghai, lot number 20100312; Methyl orange, lot number: 970924, is produced by Shanghai reagent three factory; Glacial acetic acid is produced by Shanghai reagent four factory, lot number 20100821; SD rat, ICR kind mice, provided by Qinghai Province's Experimental Animal Center.
Experimental technique and result: 1, pain model in mice, animal grouping and medication: get mice 50, be divided into 5 groups at random, if model group, positive controls (aspirin Vc enteric coatel tablets 0.4g/Kg) and Tibetan medicine embodiment 1 powder (2g/kg of the present invention, 4g/kg, 8g/kg) low, in, high dose group, gastric infusion, 20ml/Kg, every day is administered once, continuous 2d, model group is to normal saline, after last administration, 30min each Mus lumbar injection 0.6% glacial acetic acid 0.1ml/10g causes pain model in mice, observe writhing number of times in incubation period and 30min that the reaction of each group of mouse writhing occurs, the results are shown in Table 1.
Table 1 Tibetan medicine embodiment 1 of the present invention powder is on the impact (x ± s, n=10) of glacial acetic acid induced pain mice
Group Animals number dosage (g/kg) incubation period (min) writhing number of times (secondary/30min)
Model control group 10 3.43 ± 2.1744.21 ± 21.74
Positive controls 100.44.58 ± 3.2225.48 ± 7.69
Low dose group 1024.59 ± 3.8322.84 ± 6.07
*
Middle dosage group 10410.57 ± 8.21
*16.23 ± 9.75
*
High dose group 10815.46 ± 4.12
* *8.93 ± 7.62
* *
Illustrate: compare with model control group:
*p<0.05;
*p<0.01;
* *p<0.00l.
Result shows: in Tibetan medicine embodiment 1 powder of the present invention, dosage group obviously can extend the incubation period of glacial acetic acid induced pain mouse writhing reaction, more than low dose group all can reduce the number of times of writhing in 30min, compare with model control group, there is significant difference (P<0.05, P<0.01); And this effect of high dose group significantly (P<0.001).
2, mice auricle swelling model, animal grouping and medication: get mice 50, be divided into model group, positive controls (indometacin enteric-coated tablet 0.02g/Kg) and Tibetan medicine embodiment 1 powder (2g/kg of the present invention at random, 4g/kg, 8g/kg) basic, normal, high dosage group, gastric infusion, 20ml/Kg, every day is administered once, continuous 3d, and model group is to equivalent distilled water, after last medicine 1h 50 μ l dimethylbenzene are applied to mouse right ear exterior feature before and after two sides cause inflammation, and with left auricle in contrast.Cause scorching rear 30min by sacrifice, cut ears, lay the auricle of left and right ear same area with 0.9cm standard hole device.Analytical balance is weighed, and the difference of left and right auricle weight is swelling, the results are shown in Table 2.
Table 2 Tibetan medicine embodiment 1 of the present invention powder xylol causes the impact (x ± s, n=10) of mice auricle swelling
Group Animals number dosage (g/kg) ears weight difference (mg) P
Model control group 10 28.75 ± 4.69
Positive controls 100.0220.32 ± 4.97<0.01
Low dose group 10221.93 ± 5.89>0.05
Middle dosage group 10419.63 ± 6.43>0.05
High dose group 10817.18 ± 3.09<0.05
Result shows: Tibetan medicine embodiment 1 powder high dose group of the present invention can make mice auricle swelling obviously alleviate, and shows that Tibetan medicine embodiment 1 powder of the present invention has obvious antiinflammatory action.
3, hydrochloric acid-ethanol is caused to the impact of acute gastric mucosal injury: get SD rat 50, male and female half and half, be divided into 5 groups at random, be respectively: normal saline group; The basic, normal, high dosage group of Tibetan medicine embodiment 1 powder (1g/kg, 2g/kg, 4g/kg) of the present invention; XIANGSHA YANGWEI WAN positive controls (1.5g/kg).Often organize 10, before experiment, fasting can't help water 24h, after administration 1h, every rats gavaged 1.5ml hydrochloric acid-ethanol (in every 100ml hydrochloric acid-ethanol hydrochloric 1.7mL and dehydrated alcohol 60ml), after 1h, cervical dislocation puts to death rat, cuts off along greater gastric curvature, tiling, observes gastric mucosa.Ulcer index computational methods: gastric mucosa local hemorrhage is 1 point, petechial hemorrhage or erosion are respectively 1 point, and rotten to the corn 1 of wire is 3 points.Gastric ulcer suppression ratio %=(normal saline group ulcer index-medication group ulcer index)/normal saline group ulcer index × 100%, the results are shown in Table 3.
Table 3 Tibetan medicine embodiment 1 of the present invention powder causes the impact (x ± s, n=10) of acute gastric mucosal injury to hydrochloric acid-ethanol
Group Animals number dosage (g/kg) ulcer index suppression ratio (%)
Normal saline group 10 16.7 ± 5.3
Positive controls 101.56.8 ± 4.7
*60.69
Low dose group 10115.3 ± 6.8
Middle dosage group 10210.8 ± 5.6
*38.72
High dose group 1048.9 ± 4.9
*46.61
Compared with normal saline group:
*p<0.05,
*p<0.01.
Result shows: high, the middle dosage group of Tibetan medicine embodiment 1 powder of the present invention obviously can reduce the ulcer index of rat, compare with normal saline group, significant difference (P<0.05 or P<0.01) between ulcer index, shows that it has inhibitory action to the peptic ulcer that stress cause.
4, pylorus ligation is caused to the impact of acute gastric mucosal injury: get SD rat 50, male and female are regardless of, and are divided into 5 groups at random, often organize 10, be respectively: normal saline group; The basic, normal, high dosage group of Tibetan medicine embodiment 1 powder (1g/kg, 2g/kg, 4g/kg) of the present invention; XIANGSHA YANGWEI WAN positive controls (1.5g/kg).Test front fasting but can't help water 24h, under etherization fix rat, cut off 1 osculum along ventrimeson, find out stomach and ligation pylorus, duodenal administration, administration volume is 1.5ml/100g, and normal saline group gives the normal saline waiting capacity.Sew up the incision, after 4h, excess diethyl ether puts to death rat, takes out stitches and opens abdominal cavity, ligation cardia, win full stomach, cut off along greater gastric curvature, and gastric mucosa is observed in tiling.Ulcer index and ulcer index suppression ratio calculate with test method and result 1.The results are shown in Table 4.
Table 4 Tibetan medicine embodiment 1 of the present invention powder causes the impact (x ± s, n=10) of acute gastric mucosal injury to pylorus ligation
Group Animals number dosage (g/kg) ulcer index suppression ratio (%)
Normal saline group 10 12.8 ± 2.6
Positive controls 101.56.2 ± 3.3
*52.42
Low dose group 10111.4 ± 4.6
Middle dosage group 1027.6 ± 4.2
*39.23
High dose group 1044.5 ± 2.3
*64.16
Compared with normal saline group:
*p < 0.05,
*p < 0.01.
Result shows: high, the middle dosage group of Tibetan medicine embodiment 1 powder of the present invention obviously can reduce the ulcer index of rat, compare with normal saline group, significant difference (P<0.05 or P<0.01) between ulcer index, shows that it is inhibited to the peptic ulcer caused by medicine.
5, emptying on Mouse Stomach impact: get the healthy ICR kind mice 50 without wound, male and female dual-purpose, is divided into 5 groups at random by sex, body weight, 10/group, is respectively: normal saline group; The basic, normal, high dosage group of Tibetan medicine embodiment 1 powder (2g/kg, 4g/kg, 8g/kg) of the present invention; XIANGSHA YANGWEI WAN positive controls (3g/kg).Ig2 days (1 times/day) fasting but can't help water 12h and administration 1 time more afterwards, ig0.1% methyl orange 0.2ml after last administration 1h, after 20min, cervical dislocation puts to death mice, ligation cardia and pylorus, get stomach in 10ml distilled water, along greater gastric curvature, place cuts off, and is fully washed in distilled water by gastric content, adds 0.5% soda solution 5, mixing, the centrifugal 10min of 2000r/min, get supernatant and measure trap in wavelength 420nm place, the trap recorded is methyl orange trap in stomach.And add 10ml distilled water using 0.1% methyl orange 0.2ml and shake up its trap of rear measurement as radix methyl orange trap, calculate methyl orange Stomach residue rate.Methyl orange trap in methyl orange residual rate (%)=stomach/radix methyl orange trap methyl × 100%.The results are shown in Table 5.
The impact (x ± s, n=10) that table 5 Tibetan medicine of the present invention embodiment 1 powder is emptying on Mouse Stomach
Group Animals number dosage (g/kg) methyl orange residual rate (%)
Normal saline group 10 41.19 ± 9.67
Positive controls 10329.53 ± 5.14
*
Low dose group 10249.04 ± 11.36
Middle dosage group 10447.78 ± 9.16
High dose group 10831.66 ± 5.17
*
Compared with normal saline group:
*p < 0.05.
Result shows: Tibetan medicine embodiment 1 powder high dose group of the present invention can reduce methyl orange residual rate in Mouse Stomach, compare with normal saline group, difference has significant (P<0.05), illustrates that Tibetan medicine embodiment 1 powder of the present invention has facilitation to Mouse Stomach is emptying.
6, Tibetan medicine embodiment 1 powder of the present invention is on the impact of mouse small intestine ahead running: get the healthy ICR kind mice 50 without wound, male and female dual-purpose, is divided into 5 groups at random by sex, body weight, 10/group, is respectively: normal saline group; The basic, normal, high dosage group of Tibetan medicine embodiment 1 powder (2g/kg, 4g/kg, 8g/kg) of the present invention; XIANGSHA YANGWEI WAN positive controls (3g/kg).Ig2 days (1 times/day) fasting but can't help water 12h and administration 1 time more afterwards, after last administration 1h, after ig10% charcoal end 0.2ml, 15min, cervical dislocation puts to death mice, and open abdominal cavity, clip upper end is to pylorus, and lower end is to the intestinal tube of ileocecus.Measure Length of intestine as " total small intestinal length ", from pylorus to charcoal, the distance in forward position, end is as " charcoal end is at enteral advance distance ", calculates charcoal end ink propulsive rate.Charcoal end ink propulsive rate=charcoal end is at enteral advance distance/small intestinal total length × 100%.The results are shown in Table 6.
The impact (x ± s, n=10) that table 6 Tibetan medicine embodiment 1 of the present invention powder advances small intestine movement of mice
Group Animals number dosage (g/kg) small intestinal length (cm) charcoal end advance distance (cm) ink propulsive rate (%)
Normal saline group 10 53.3 ± 2.1641.4 ± 3.3777.15 ± 6.13
Positive controls 10349.6 ± 4.1544.5 ± 6.2891.37 ± 12.19
*
Low dose group 10248.3 ± 5.7137.2 ± 6.1479.33 ± 9.17
Middle dosage group 10449.4 ± 3.6343.5 ± 6.5488.63 ± 9.15
*
High dose group 10849.6 ± 4.2346.7 ± 5.16
*96.15 ± 6.17
*
Compared with normal saline group:
*p<0.05;
*p<O.0l.
Result shows: the middle and high dosage group of Tibetan medicine embodiment 1 powder of the present invention can promote mouse small intestine charcoal end advance distance, compare with normal saline group, difference has significant (P<0.05 or P<0.01), show that Tibetan medicine embodiment 1 powder of the present invention has the ahead running promoting intact animal's small intestinal, strengthen the function of enterokinesia.
The clinical observation on the therapeutic effect of [test example 2] Tibetan medicine embodiment 1 powder treatment of the present invention chronic atrophic gastritis:
Physical data: 70 routine Chronic Atrophic Gastritis Patients are divided at random treatment group 35 example and matched group 35 example, male 22 examples (62.9%) in treatment group, female 13 example (37.1%); 28-69 years old ages, average (43.8 ± 6.4) year, the course of disease 11-133 months, average (66 ± 17) moon; Male 24 examples (68.6%) in matched group, female 11 example (31.4%); 29-70 years old ages, average (44.6 ± 5.6) year, the course of disease 11-131 months, average (65 ± 16) moon, two groups of physical data differences do not have statistical significance, have comparability.
Therapeutic Method: treatment group gives Tibetan medicine embodiment 1 powder of the present invention, ante cibum, warm water delivery service, 1.5g/ time, 3 times/day, was used in conjunction 1-3 months.Matched group gives stomach that health (Shiyiting Pharmaceutical Factory, Harbin pharmaceutical Industry Group) conventional therapy, is used in conjunction 1-3 months.
Criterion of therapeutical effect: according to chronic gastritis combination of Chinese and Western medicine syndrome differential diagnosis and criterion of therapeutical effect determination clinical efficacy.Observe treatment Patients Before And After symptom and sign and improve situation, and mark, asymptomatic is 0 point, and mild symptoms is 2 points, in symptom be 4 points, severe symptoms is 6 points, carries out gastroscope gastric mucosa item pathologic finding, evaluates two groups of clinical efficacies, clinical symptom disappearance, gastric mucosa transference cure, HP removes as curing; Clinical symptoms substantially disappears or alleviates, and gastric mucosal lesions alleviates or extent of disease is reduced into improvement; Clinical symptoms and gastric mucosal lesions invalid without being improved as.Total effective rate=(curing case load+improvement case load)/total case load.The results are shown in Table 7,8.
Before and after table 7 liang group treatment, symptom score compares (x ± s)
Group treatment time stomachache feeling of fullness indigestion and loss of appetite vomiting belch pantothenic acid
Treatment group treatment front 4.96 ± 1.161.22 ± 0.572.28 ± 1.141.53 ± 1.081.47 ± 0.85
0.42 ± 0.580.18 ± 0.070.26 ± 0.160.15 ± 0.130.23 ± 0.16 after treatment
4.76 ± 1.381.22 before treatment of control group ± 0.672.29 ± 1.131.56 ± 0.851.47 ± 0.93
1.27 ± 0.640.37 ± 0.260.68 ± 0.340.47 ± 0.350.49 ± 0.28 after treatment
Stomachache after treatment group and treatment of control group, feeling of fullness, indigestion and loss of appetite, vomiting, the scoring of belch pantothenic acid all comparatively obviously reduce before treatment, difference has statistical significance (P<0.01), treatment group treatment after stomachache, feeling of fullness, indigestion and loss of appetite, vomiting, belch pantothenic acid mark be starkly lower than matched group, difference has statistical significance (P<0.01).
Table 8 liang group Clinical efficacy comparison (example, %)
Group number of cases cures the invalid total effective rate that takes a turn for the better
Treatment group 351416585.71
*
Matched group 3510141168.57
Compare with matched group:
*p<0.05.
All do not occur untoward reaction in two groups of therapeutic processes, clinical observation result shows: Tibetan medicine embodiment 1 powder treatment chronic atrophic gastritis determined curative effect of the present invention, clinic is promoted the use of, and has good application prospect.
In the preparation of conventional oral solid formulation dosage form, powder be prepared in other conventional oral solid formulation preparation process the process portion belonged to above, the test example of powder demonstrates has good effect in treatment chronic atrophic gastritis, also just describes the pill in conventional oral solid formulation dosage form, granule, capsule, tablet also have same effect; Namely the above-mentioned embodiment 1-5 enumerated has same effect.Illustrate that Tibetan medicine of the present invention has good effect in treatment chronic atrophic gastritis.
Claims (4)
1. treat the preparation method of atrophic gastritis Tibetan medicine for one kind, it is characterized in that comprising the following steps: that this Tibetan medicine is made up of active component or is made up of active component and pharmaceutically acceptable adjuvant, wherein said active component is made up of the crude drug of following concrete weight proportion: Semen Granati 37.5 ~ 112.5g, Cortex Cinnamomi 25 ~ 75g, Fructus Amomi Rotundus 25 ~ 75g, Fructus Piperis Longi 25 ~ 75g, Flos Carthami 5 ~ 15g, Rhizoma Zingiberis 5 ~ 15g, Fructus Piperis 5 ~ 15g, Sal Ammoniacus 5 ~ 15g, Capsicum frutescens Linn. 5 ~ 15g, Tibetan Caulis Akebiae 12.5 ~ 37.5g, Flos Bombacis Malabarici 12.5 ~ 37.5g; Mixing, adopts comminuting method or decoction and alcohol sedimentation technique or ethanol extract from water precipitation to make active component.
2. the preparation method of Tibetan medicine according to claim 1, wherein takes the crude drug of following concrete weight proportion: Semen Granati 60 ~ 90g, Cortex Cinnamomi 40 ~ 60g, Fructus Amomi Rotundus 40 ~ 60g, Fructus Piperis Longi 40 ~ 60g, Flos Carthami 8 ~ 12g, Rhizoma Zingiberis 8 ~ 12g, Fructus Piperis 8 ~ 12g, Sal Ammoniacus 8 ~ 12g, Capsicum frutescens Linn. 8 ~ 12g, hide Caulis Akebiae 20 ~ 30g, Flos Bombacis Malabarici 20 ~ 30g.
3. the preparation method of Tibetan medicine according to claim 2, wherein takes the crude drug of following concrete weight: Semen Granati 75g, Cortex Cinnamomi 50g, Fructus Amomi Rotundus 50g, Fructus Piperis Longi 50g, Flos Carthami 10g, Rhizoma Zingiberis 10g, Fructus Piperis 10g, Sal Ammoniacus 10g, Capsicum frutescens Linn. 10g, hide Caulis Akebiae 25g, Flos Bombacis Malabarici 25g.
4., according to the preparation method of any one Tibetan medicine described in claim 1-3, it also comprises the following steps: active component and pharmaceutically acceptable adjuvant to make powder, pill, granule, capsule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410206297.7A CN103948900B (en) | 2014-05-16 | 2014-05-16 | A kind of preparation method for the treatment of atrophic gastritis Tibetan medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410206297.7A CN103948900B (en) | 2014-05-16 | 2014-05-16 | A kind of preparation method for the treatment of atrophic gastritis Tibetan medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103948900A CN103948900A (en) | 2014-07-30 |
| CN103948900B true CN103948900B (en) | 2016-03-30 |
Family
ID=51326340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410206297.7A Active CN103948900B (en) | 2014-05-16 | 2014-05-16 | A kind of preparation method for the treatment of atrophic gastritis Tibetan medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103948900B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593507A (en) * | 2004-06-30 | 2005-03-16 | 穆静敏 | Chinese prepared drug for treating gastropathy and its preparation method |
| CN103386094A (en) * | 2012-05-08 | 2013-11-13 | 陈�田 | Medicine used for treating chronic gastritis |
-
2014
- 2014-05-16 CN CN201410206297.7A patent/CN103948900B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593507A (en) * | 2004-06-30 | 2005-03-16 | 穆静敏 | Chinese prepared drug for treating gastropathy and its preparation method |
| CN103386094A (en) * | 2012-05-08 | 2013-11-13 | 陈�田 | Medicine used for treating chronic gastritis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103948900A (en) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101849999B (en) | Chinese medicinal composition for treating pelvic inflammation and preparation method thereof | |
| CN103301400B (en) | A kind of Chinese medicine composition and preparation method for the treatment of chronic atrophic gastritis | |
| CN102106965B (en) | Composition for treating acute injury of soft tissue and application thereof | |
| CN103948899B (en) | A kind of Tibetan medicine for the treatment of atrophic gastritis | |
| CN103933450A (en) | Traditional Chinese medicine composition for preventing or/and treating gastrointestinal diseases and preparation method of composition | |
| CN103830657A (en) | Medicine for treating chronic cholecystitis | |
| CN103356802B (en) | Medicament for treating mastitis, and preparation method thereof | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN103735647A (en) | Medicated wine for treating chronic infectious arthritis | |
| CN103948900B (en) | A kind of preparation method for the treatment of atrophic gastritis Tibetan medicine | |
| CN103071076A (en) | Traditional Chinese medicament composition for promoting recovery after cesarean section by lavipeditum nursing and application | |
| CN103446545B (en) | Traditional Chinese medicine composition for treating chronic atrophic gastritis and preparation method thereof | |
| CN103041233A (en) | Pharmaceutical composition for treating infantile diarrhea and preparation method thereof | |
| CN105168628A (en) | Medicine for treating cellulitis and preparation method thereof | |
| CN103893732B (en) | A kind of Tibetan medicine treating chronic gastritis | |
| CN102441131A (en) | Chinese medicinal composition for treating traumatic injury | |
| CN105521332A (en) | Traditional Chinese medicinal composition for treating anal fissure, and preparation method and application thereof | |
| CN103893432A (en) | Pharmaceutical composition for treating fracture and soft tissue injury and preparation method of pharmaceutical composition | |
| CN103816411A (en) | Medicine for treating gallstones and preparation method thereof | |
| CN103893733A (en) | Preparation method of traditional Tibetan medicine for treating chronic gastritis | |
| CN105168834A (en) | Medicine for treating scrofula and preparation method thereof | |
| CN100381157C (en) | Externally applied medicine for treating gynecological inflammation and abdominal mass | |
| CN105287798A (en) | Lipid-lowering and slimming recovery pill | |
| CN103070998B (en) | Externally-applied plaster for curing pain of rheumatic joints | |
| CN103768536B (en) | A kind of Chinese medicine for the treatment of dysmenorrhea and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |